In Vitro Technologies

Permits and Restrictions	View Permits View Restrictions
Organism	Homo sapiens, human
Tissue	lung
Product Format	frozen
Morphology	epithelial
Culture Properties	suspension, multicell aggregates
Biosafety Level	1 Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country.
Disease	papillary adenocarcinoma
Age	48 years
Gender	male
Ethnicity	Caucasian
Applications	This line was derived by A.F. Gazdar, H.K. Oie, J.D. Minna and associates from a lymph node metastasis obtained from a patient prior to therapy. Ultrastructural studies demonstrated the presence of cytoplasmic structures characteristic of Clara cells.
Storage Conditions	liquid nitrogen vapor phase

Derivation	This line was derived by A.F. Gazdar, H.K. Oie, J.D. Minna and associates from a lymph node metastasis obtained from a patient prior to therapy.
Clinical Data	This line was derived by A.F. Gazdar, H.K. Oie, J.D. Minna and associates from a lymph node metastasis obtained from a patient prior to therapy. male Caucasian 48 years
Genes Expressed	surfactant associated protein A (SP-A); surfactant associated protein B (SP-B)
Cellular Products	surfactant associated protein A (SP-A); surfactant associated protein B (SP-B)
Tumorigenic	Yes
Effects	Yes, the cells produce tumors in athymic nude mice
Comments	This line was derived by A.F. Gazdar, H.K. Oie, J.D. Minna and associates from a lymph node metastasis obtained from a patient prior to therapy. Ultrastructural studies demonstrated the presence of cytoplasmic structures characteristic of Clara cells. The cells express protein and RNA of SP-A, the major surfactant associated protein, and SP-B. SP-C RNA was not expressed.

Complete Growth Medium	ACL-4 medium (serum-free)The base medium for this cell line is ATCC formulated DMEM: F12 Medium Catalog No. 30-2006. To make the complete growth medium, add the following components to the base medium: 0.02 mg/ml insulin 0.01 mg/ml transferrin 25 nM sodium selenite (final conc.) 50 nM Hydrocortisone (final conc.) 1 ng/ml Epidermal Growth Factor (do not filter) 0.01 mM ethanolamine (final conc.) 0.01 mM phosphorylethanolamine (final conc.) 100 pM triiodothyronine (final conc.) 0.5% (w/v) bovine serum albumin (final conc.) 10 mM HEPES 0.5 mM sodium pyruvate (final conc.) extra 2mM L-glutamine (for final conc. of 4.5mM)
Subculturing	Protocol: Cultures can be maintained by addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation of the suspension with subsequent resuspension in fresh medium. Add medium as the cell density increases. Medium Renewal: Every 2 to 3 days
Cryopreservation	Freeze medium: Complete growth medium supplemented with 10% fetal bovine serum and 5% (v/v) DMSO Storage temperature: liquid nitrogen vapor phase
Culture Conditions	Atmosphere: air, 95%; carbon dioxide (CO2), 5% Temperature: 37.0°C

STR Profile	Amelogenin: X CSF1PO: 10 D13S317: 9,14 D16S539: 12 D5S818: 12 D7S820: 11,14 THO1: 7,9.3 TPOX: 9,11 vWA: 19

Name of Depositor	AF Gazdar, JD Minna
References	Gazdar AF, et al. Peripheral airway cell differentiation in human lung cancer cell lines. Cancer Res. 50: 5481-5487, 1990. PubMed: 2386953 NCI-Navy Medical Oncology Branch Cell Line Supplement. J. Cell. Biochem. suppl. 24: 1996.

Name of Depositor

AF Gazdar, JD Minna

References

Gazdar AF, et al. Peripheral airway cell differentiation in human lung cancer cell lines. Cancer Res. 50: 5481-5487, 1990. PubMed: 2386953

NCI-Navy Medical Oncology Branch Cell Line Supplement. J. Cell. Biochem. suppl. 24: 1996.

NCI-H1404; Lung Papillary; Human (Homo sapiens) Item ID: ATCCRL5819